Summary The present study represents a continuation of previous works in which we observed that lung carcinomas co-expressing MDM2 protein and p53 mutants (mt p53) exhibited more aggressive behaviour. In the above studies, we suggested a 'gain of function' mechanism of mt p53 proteins based on the fact that the MDM2 gene possesses a p53-responsive element (MDM2-p53RE). In this study, to prove our hypothesis, we selected 12 cases from a series of 51 bronchogenic carcinomas. In these 12 cases, we examined the ability of the expressed mt p53 to bind the MDM2-p53RE and correlated the findings with MDM2 expression. Furthermore, we constructed four of these p53 mutants and studied their transactivation properties by co-transfecting them with a reporter plasmid carrying MDM2-p53RE in the p53 null non-smallcell lung carcinoma cell line (NSCLC) H1299. We observed mutant p53 protein DNA-binding activity, which depended on the nature and the position of the amino acid substitution. The fact that the cases with DNA-binding activity were accompanied with MDM2 protein isoforms' overexpression is indicative of a 'gain of function' phenotype. This hypothesis was enforced by the findings of the transfection experiments, which revealed that certain p53 mutants enhanced the expression of the luciferase reporter gene either directly or indirectly via a dominant positive effect on the wild-type p53. In conclusion, this work is one first attempt to examine if the deregulation of the p53/MDM2 autoregulatory feedback loop is due to novel properties of certain p53 mutants in the specific environment of a subset of bronchogenic carcinomas.
following sequence: 5' (Pu)3C(A/T)(A/T)G(Py)3 3' (Funk et al, 1992) . The list of genes that possess these DNA sites is rapidly increasing and includes: waf-J/cip-J (El-Deiry et al, 1993), gadd45 (Kastan et al, 1992 and references therein), MDM2 (Zauberman et al, 1995a) , bax (Miyashita and Reed, 1995) , cyclin G (Zauberman et al, 1995b) , insulin-like growth factor binding protein 3 (IGF-BP3) (Buckbinder et al, 1995) , epidermal growth factor receptor (EGF-r) (Deb et al, 1994) , transforming growth factor-a (TGF-a) (Shin et al, 1995) , proliferating cell nuclear antigen (PCNA) (Morris et al, 1996) , thrombospondin-J (Dameron et al, 1994) , fas/APO-1 (Owen-Schaub et al, 1995) , Rb (Osifchin et al, 1994) , cyclin D , ras (Spandidos et al, 1995; Zhang et al, 1995) and p53 itself (Deffie et al, 1993) .
The MDM2 gene is located on chromosomal region 12ql3-14 and has the characteristic of generating various MDM2 proteins . The full-length MDM2 gene product p90 forms an autoregulatory feedback loop with p53, which seems to be critical for normal cell proliferation Oca Luna et al, 1995) . The functions of the other MDM2 proteins are currently unknown. The expression of different MDM2 protein isoform pattems in leukaemias and lymphomas (Bueso-Ramos et al, 1995a) , sarcomas (Bueso-Ramos et al, 1995b) , breast (BuesoRamos et al, 1996) and lung carcinomas (Gorgoulis et al, 1996b) but not in normal tissue, suggests that certain MDM2 proteins may play a role in the oncogenic process. Interestingly, in leukaemias, lymphomas, sarcomas and ovarian carcinomas (Foulkes et al, 1995) , MDM2 overexpression does not accompany p53 mutations or overexpression, suggesting a novel p53-independent pathway of action. Recently, we reported that MDM2 protein isoforms are overexpressed and coexist with the mutant p53 protein (mt p53) in a subset of bronchogenic carcinomas. This association was accompanied with a more aggressive behaviour (Gorgoulis et al, 1996a,b) . We suggested that this may be indicative of mt p53-MDM2 complex activity (Momand et al, 1992) or may reflect a 'gain of function' phenotype. The last hypothesis is based on recent studies that show that mt p53 does not only act by dominant negative inhibition of wild-type p53 (wt p53) (Hinds et al, 1989; Milner et al, 1991) but also exerts oncogenic properties of its own (Michalovitz et al, 1991; Chin et al, 1992; Dittmer et al, 1993; Hsiao et al, 1994; Muller et al, 1996) . One putative mechanism by which mt p53 could acquire tumorigenic properties is to constantly stimulate growth-promoting genes that contain the p53-specific DNA binding site. This could be achieved if the mt p53 maintained its ability to bind and transactivate the above-mentioned DNA elements.
In the present study, we examined the last hypothesis by testing the ability of mt p53 forms, detected in selected cases of bronchogenic carcinomas, to bind the p53-responsive element (p53RE) of the growth-promoting gene MDM2 and correlating the findings with its expression. Furthermore, we constructed four of these p53 mutants and studied their transactivation properties by co-transfecting them with a reporter plasmid carrying the MDM2-p53RE in the p53 null non-small-cell lung carcinoma cell line (NSCLC) H1299.
MATERIALS AND METHODS

Tissue samples
Fifty-one bronchogenic carcinomas were taken shortly after surgery. Two samples of each tumour were obtained. One was snap frozen in liquid nitrogen and stored at -70°C; the other was formalin fixed and paraffin embedded (FFPE). In addition, adjacent normal tissue was included from each specimen examined. The patients had not undergone any chemo-or radiotherapy before surgical resection, thus avoiding up-and down-regulation of p53 and MDM2 proteins (Price and 
MDM2 and p53 immunohistochemistry (IHC)
Immunohistochemical analysis was performed on tissue sections using the streptavidin-biotin-peroxidase method (Dako, Denmark). p53 and MDM2 protein were unmasked with the heat-mediated antigen retrieval (HMAR) method, as previously described (Gorgoulis et al, 1996a, b Simultaneous extraction of nuclear proteins and DNA The samples were homogenized in a hypotonic buffer [25 mM Tris-HCl pH 7.5, 5 mM potassium chloride, 0.5 mm magnesium chloride, 0.5 mm dithiothreitol (DTT), 0.5 mm polymethylsulphonyl fluoride (PMSF)] at 5-10 mg ml-l. The nuclei were collected in a pellet at 2500 r.p.m. for 10 min at 4°C, washed three times with an isotonic buffer (25 mm Tris-HCl pH 7.5, 5 mm potassium chloride, 0.5 mm magnesium chloride, 0.2 mm sucrose, 0.5 mM DTT, 1 mm PMSF) and resuspended in nuclear extraction buffer (25 mm Tris-HCl pH 7.5, 1 mm EDTA, 0.1% NP-40, 0.5mM DTT, 0.5 mm PMSF). Nuclear extracts were clarified after centrifugation at 25 000 r.p.m. for 60 min at 40C. Supematant containing the extracts was stored at -70°C. DNA was extracted from the final pellet, which contained a mixture of nucleic acids and nuclear debris, according to standard protocols (Sambrook et al, 1989) .
Nested-PCR/SSCP and solid phase sequencing of p53 gene Nested PCR and SSCP analysis
The methods were performed on matched normal and tumour DNA, as described previously (Gorgoulis et al, 1995a) . Briefly, we first determined the optimal conditions for amplification of the 2.9 kb p53 gene fragment, which contains exons 4-9, and then we amplified individual exons, with nested PCR, using biotinylated sense primers. Next, we analysed, using the SSCP technique, exons 4-9, as the majority of previous studies have shown that p53 mutations in lung carcinomas are found in this region (Greenblatt et al, 1994) . The exons that showed mobility shifts were further analysed with solid-phase sequencing.
Immobilization of the PCR product
The biotinylated PCR product was immobilized on magnetic beads covalently coupled with streptavidin (Dynabeads M-280-streptavidin, Dynal, Oslo, Norway) using a neodynium-iron-boron permanent magnet (Dynal, Oslo, Norway) . Briefly, 40 g1 of PCR product was added to 40 gl of dynabeads M-280 streptavidin and was incubated for 30 min at room temperature (RT). The beads were previously washed with 2X binding and washing buffer (2X B&W) (10 mM Tris-HCl pH 7.5, 1 mM EDTA, 2 M sodium chloride). Then, the mixture containing the complex was placed in the magnet. The supernatant was removed and 8 p1 0.1 N sodiumhydroxide was added. The sodium hydroxide supematant containing the eluted single strand was placed in a new tube and neutralized with 0.2 N hydrochloric acid and 1 M Tris-HCl pH 7.5. The remaining immobilized single strand was washed once with 0.1 N sodium hydroxide once with lxB&W buffer and once with TE (10 mM Tris-HCl pH 7.4, 0.1 mM EDTA pH 8) and diluted in 7 p1 of double-distilled water.
Sequencing
Direct sequencing of the eluted and immobilized strand was carried out with standard dideoxy termination reactions using the Sequenase version 2.0, DNA Sequencing kit (US Biochem, Cleveland, USA). In brief, 2 ul (2 pmol) of sequencing primer was added to each single-strand tube together with 2 pl of annealing buffer. The annealing mixture was heated for 2 min at 65'C and allowed to cool to RT for 30 min. Then 2 pl of diluted labelling mixture (dGTP, dCTP, dTTP), 0.5 p1 of [a-35S]dATP and 2 pl (2.5 U 1-1) of T7 DNA polymerase were placed in each annealing mixture and prewarmed for 2 min at RT. Consequently, 3.5 p1 of the reaction was added to four tubes containing 2.5 p1 of the termination mixtures and were incubated for a further 5 min. The reactions were stopped with a solution containing formimide. Termination reactions were heated for 2 min at 90°C and 2-3 p1 was run on a 8% polyacrylamide denaturating gel. The gels were dried and exposed to radiograph film (RX Fuji) at RT.
The sequencing primers used were the following. For exon 5: biotinylated strand, 5'-TTC AAC TCT GTC TCC TTC CT-3' and non-biotinylated strand, 5'-CAG CCC TGT CGT CTC TCC AG-3'; for exon 6: biotinylated strand, 5'-GCC TCT GAT TCC TCA CTG AT-3' and non-biotinylated strand, 5'-TTA ACC CCT CCT CCC AGA GA-3'; for exon 7: biotinylated strand, 5'-TGT GCA GGG TGG CAA GTG GC-3' (non-biotinylated strand-sequencing was not performed), and for exon 8: biotinylated strand: 5'-TTC CTT ACT GCC TCT TGC TT-3' and non-biotinylated strand: 5'-TGA GGC ATA ACT GCA CCC TTG GT-3'.
Southern blot analysis for LOH of the chromosomal region 17p13.3
An aliguot (10 jig) of DNA was digested with PstI (Boehringer Mannheim Biochemica, Mannheim, Germany). The resulting fragments were subjected to electrophoresis in 0.8% agarose gels, transferred to nylon membranes (Hybond-N, Amersham) and baked for 3 h at 800C. The membranes were hybridized to random primer [32P]dCTP-labelled pYNZ22 probe, which locates chromosomal region 17pl3.3. This probe detects restriction fragments length polymorphisms on PstI and BamHI digested DNA. After hybridization, the membranes were washed under stringent conditions (0.2 x SSC at 65°C for 20 min) and autoradiographed.
Differential PCR (D-PCR) for MDM2 gene amplification D-PCR was carried out as described previously (Gorgoulis et al, 1995b) . As target and reference sequences we used a 150-bp and a 230-bp fragment of the MDM2 (Fontana et al, 1994) , and Functions of mutant p53 and MDM2 proteins in lung cancer 377 interferon-,y (IFN-y) (Gorgoulis et al, 1995b) respectively. The primer sequences for the 230-bp MDM2 gene fragment were the following: 5'-TGAGTGAGAACAGGTGTCACC-3' (sense) and 5'-TTCTAGATGAGGTAGATG-3' (antisense). A leiomyosarcoma carrying an eightfold MDM2 gene amplification was used as positive control.
RNA extraction -MDM2 Northern blotting RNA was extracted from the specimens using the RNazol B reagent (BioGenesis) and Northern blot hybridization was performed with a 585-bp MDM2 [32P]dCTP-labelled probe spanning nucleotidies 650-1214 of the published cDNA sequence as described previously (Gorgoulis et al, 1996a ).
MDM2 and p53 Western blot analysis -MDM2 immunoprecipitation
An aliquot (20 gg) of nuclear proteins was electrophoresed on 10% polyacrylamide-SDS gel and transferred to nitrocellulose membrane (Sambrook et al, 1989) . Blots were blocked for 2 h in 5% non-fat dry milk/PBST (PBST: PBS, 0.1% Tween-20) at RT. Subsequently, the membranes were incubated overnight with IBlO and IF2 antibodies (diluted 1:500) and DOI (diluted 1:1000) at 4°C. For detection, the biotinylated rabbit anti-mouse immunoglobulin (1:100) (Dako, Denmark) and streptavidine-biotin-peroxidase complex (Dako, Denmark) were applied. The MDM2 and p53 levels were analysed using an enhanced chemiluminescence system (Amersham, Arlington Heights, IL, USA). Protein from a leiomyosarcoma, overexpressing MDM2, and normal lung tissue, with undetectable levels of MDM2 protein were used as positive and negative control respectively. Protein from the HT29 colon cancer cell line, which overexpresses p53, was used as a positive control (American Type Culture Collection). Band sizes were determined by comparison to migration of broad range protein ladder (Biolabs, MA, USA). Protein levels of MDM2 were scored by eye on a relative basis as follows: 0, negative; (+), low levels; (++), elevated levels.
The specificity of the bands immunoblotting showed, was verified by immunoprecipitating the nuclear extracts from the selected cases. Immunoprecipitation was performed using protein ASepharose (Sigma), according to standard protocols (Sambrook et al, 1989) . Immunoprecipitates were then separated on a 10% polyacrylamide gel and immunoblotted.
Electrophoretic mobility shift assay (EMSA) The p53RE of the MDM2 gene The p53RE of the MDM2 contains two p53 binding sites (underlined italic regions), separated by 18 nucleotides (Zauberman et al, 1995a) . The sequence of this region is: 5'-TTGAGCT-GGTCAAGTTCAGACACGTTC-CGAAACTGCAGTAAAAG-GAGTTAAGTCCTGACTTTGTCT-CCAGCTC-3'. The above oligonucleotides (sense, anti-sense) were synthesized on a Cyclone Plus synthesizer (Milligan Bioresearch, MA, USA). Endlabelling was performed using T4 polynucleotide kinase (Boehringer, Mannheim, Germany) and [a-32P]ATP according to standard protocols (Sambrook et al, 1989) . The end-labelled oligonucleotides were mixed in 0.1 M sodium chloride, heated at 950C for 5 min and then gradually cooled to RT to allow annealing.
Controls
In vitro translated p53 protein was used as a positive control in the DNA binding experiments. Briefly, the procedure was the following: the expression vector pGEMhp53wtB was linearized by digestion with BamHI. Capped transcripts were prepared using T7 RNA polymerase (Promega) and then translated in reticulocyte lysates as recommended by the supplier (Promega). Successful translation was verified by Western blotting using antibody DOI. The SP-1 oligonucleotide was used as a p53-unrelated oligonucleotide competitor.
DNA binding assay Three microlitres of nuclear extracts (10 jg) was preincubated for 10 min with 100 ng of purified monoclonal antibody PAb421 to activate specific DNA binding of p53 protein. It has been shown that p53 binds non-specifically to DNA through the carboxyterminal domain, locking p53 in a conformation that cannot bind its specific element. By adding PAb421, non-specific binding is inhibited and p53 adopts the specific DNA conformation (Halazonetis et al, 1993; Bayle et al, 1995) . Furthermore, nuclear extracts from p53 null cells (Saos2) were added to the reaction, in order to get in vitro translated p53 to bind the p53RE (Funk et al, 1992) . Subsequently, 1 ng of labelled p53RE in the presence of 500 ng of poly(dI)-poly(dC) as non-specific DNA competitor was added. All incubations took place on ice with the following binding conditions: 50 mm potassium chloride, 25 mm Hepes, pH 7.6,5 mm DTT, 10 jg of leupeptin per ml, 0.05% Triton X-100 and 20% glycerol. Competition experiments were performed by preincubating PAb421-activated extracts with 50-fold molar excess of unlabelled oligonucleotides (pS3RE or SP-1) or 100 ng of anti-p53 antibody DO1. Protein-DNA binding reactions were analysed on a 4% polyacrylamide gel. Gels were dried and exposed on radiograph film (RX Fuji) at -70°C.
Transfection assays Cell line and plasmids H1299 cells (a human non-small-cell lung carcinoma cell line that contains a homogeneous deletion of the p53 gene) were obtained from the American Type Culture Collection (Rockville, MD, USA) and maintained in RPMI-1640 medium supplemented with 10% fetal calf serum in a 37°C incubator containing 5% carbon dioxide. Reporter plasmid pGL2hmdm-HX-luc was constructed, as described previously (Zauberman et al, 1995a) , by excising the HindIII-XhoI fragment from the amplified hMDM2 DNA, and subcloning it into pGL2-Basic (Promega). The representative p53 mutants, V157F, R209T (group A), V173E (group B) and R273H (group C), were generated by site-directed mutagenesis of the parental wtp53 vector pCB6p53wt. The pCB6p53wt plasmid contains the published p53 cDNA sequence (Matlashewski et al, 1984; Zakut-Houri et al, 1985) .
Site-directed mutagenesis
The site-directed mutagenesis procedure we followed was based on the method of Deng and Nickoloff (1992) . This method works by simultaneously annealing two oligonucleotide primers to one strand of a denaturated double-strand plasmid. One primer introduces the desired mutation (mutagenic primer), whereas the other eliminates a unique restriction site of the plasmid for the purpose of selection (selection primer). After synthesis of a hybrid plasmid and a primary selection by digesting with the appropriate restriction enzyme, the , to the p53RE of the MDM2 gene. Lane 1, mutant p53 R209T binds with the specific DNA, in the presence of PAb421, and forms a retarded band (middle arrow). The specificity of the band was demonstrated with the following reactions. Lane 2, 50-fold molar excess of unlabelled MDM2-p53RE probe, in the presence of PAb421, markedly diminished the retard band. Lane 3 (control), in vitro translated wild-type p53 was incubated with labelled p53-RE, in the presence of PAb421, and produced a retard band at the same height as R209T.*: In the last reaction we added nuclear extracts from the p53 null cell line Saos2 to achieve p53 specific binding (Funk et al, 1992) . Lane 4, the addition of anti-p53 antibody DO-1, in the presence of PAb421, super-shifted the retard band indicating the presence of p53 in the protein-p53 complex (Niewolik et al, 1995) (upper arrow). (C) Western blotting with antibody 1 Bl0 showing the MDM2 protein isoform p76/74 expressed in sample 5 (lane 5). Lanes 1-4 represent MDM2 proteins produced from cases included in our previous work (Gorgoulis et al, 1996b) hybrid plasmid is transformed into a mutS E. coli strain defective in a mismatch repair. This step is followed by an amplification procedure that results in a large pool of mutated and parental plasmids. The isolated DNA is then subjected to a series of selective restriction enzyme digestions that destroy the parental plasmid. A final transformation using the thoroughly digested DNA will result in the recovery of the desired mutant plasmid. In the present study, we used a selective primer which eliminates the unique NdeI restriction site and introduces an NcoI restriction site in the parental plasmid pCB6p53wt, and mutagenic primers:
for V157F: 5'-GGCACCCGCTTCCGCGCCATGGC-3' for R209T: 5'-TTGGATGACACAAACACTlTTCGAC-3' for V173E: 5'-GACGGAGGTTGTGAGGCGCTGCC-3' Functions of mutant p53 and MDM2 proteins in lung cancer 379 
RESULTS
Immunohistochemical and molecular profile of p53 and MDM2 proteins in the selected bronchogenic carcinomas (Table 1) The data concerning the characteristics of p53 and MDM2 proteins in the selected cases of groups A (cases 1-5), B (cases 6-8) and C (cases 9-12) are presented in detail in Table 1 . All the mutations were single-base substitutions and missense (six transversions and four transitions) (Figure lA) with the exception of a frame-shift mutation detected in case 9. In cases 1-4, they were located in the 3 sandwich of the p53 protein (S4, S8, S4 and S9, respectively, Cho et al, 1994) that forms a scaffold to support the DNA-binding domain. This region of p53 is less conserved than the DNA-binding domain and possesses less than 1% of all p53 mutations. Mutations detected in this area are known as conformational. In specimen 5, the mutation was also conformational with the difference that it occurred in a 5-turn connecting S6 and S7 (Cho et al, 1994) . The mutations in group B and in specimens 10 and 11 of group C were located in the DNA-binding domain and are classified as contact mutants (Cho et al, 1994 Figure 1C ). D-PCR analysis showed that overexpression of the MDM2 proteins was due to increased transcription and not to MDM2 gene amplification.
DNA binding properties of mutant p53 proteins (Table 1 (wt p53) protein is expressed at very low levels and plays little role in the normal cell cycle (Vogelstein et al, 1992) . The MDM2 gene is very weakly stimulated by wt p53 and the low levels of the MDM2 protein p90 are produced mainly due to the basal activity of the P1 promoter (Zauberman et al, 1995a) . (B) In a normal cell under stress (DNA damage, hypoxia, metabolic changes and immunological response), the MDM2 gene is expressed only when wt p53 has activated the targets that mediate its 'protective' action (e.g. gadd45, waf-1/cip-1). When the cell contains relatively large amounts of wt p53, it binds transiently the p53 RE of MDM2, triggerng the production of MDM2 protein p90 that eventually terminates p53 cycle arrest mediated signal (reviewed by Gottlieb and Oren, 1996; Ko and Prives, 1996; Oren and Prves, 1996; Levine, 1997) . Furthermore, p90 promotes the cell cycle by inactivating the oncosuppressor protein Rb (Xiao et al, 1995) and enhancing the activity of the S-phase inducing transcription factor E2F1 (Martin et al, 1995) . (C) In the environment of a lung carcinoma cell the following oncogenic mechanisms may possibly develop: 1. Constantly elevated levels of mutant p53 proteins permanently stimulate the MDM2 gene (directly or indirectly, see Discussion) producing high levels of MDM2 mRNA. Excess MDM2 mRNA is probably responsible, via a complex dosedependent mechanism (Zauberman et al, 1995a; Barak et al, 1994) , for the production of various MDM2 proteins, several of which do not form an autoregulatory loop with p53 (Gorgoulis et al, 1996b) . The overexpressed p90 isoform positively augments cell proliferation by interacting with E2F1. The other MDM2 proteins, probably, add novel oncogenic properties to the cell (Shigalas et al, 1996) . 2. Inactive mt p53 proteins exert a dominant positive effect on the transcription activity on the wt p53 protein. 3. Alterations at the P1 promoter may activate a p53-independent mechanism of MDM2 overexpression. 4. Mutant p53 has the ability to complex with the MDM2 p90 isoform enhancing probably the tumorigenic potential (Momand et al, 1992) 1995) and revealed that p53 mutants V157F, Y234C and R209T
( Fig. lA) maintained the wild-type p53 property to bind the MDM2-p53RE. Interestingly, the substituted amino acids in the first two specimens possessed similar residual (-R) groups. In case 1, the hydrophobic non-polar Val was replaced by Phe and in case 2 the hydrophilic uncharged Tyr was replaced by Cys. In contrast, in case 5, at position 209, the hydrophilic uncharged amino acid Thr took the place of the positive charged Arg. Finally, mutants R158G (case 3) and E258G (case 4) showed no DNA binding activity. The substituted amino acids in these specimens also belonged to different classes. More specifically, the positively charged Arg and the negatively charged Glu were replaced by the uncharged hydrophilic Gly.
Group B The p53 mutants of this group, A138D, A138S and V173E, did not interact with the MDM2-p53RE. It is notable that the first two cases possessed a point mutation at the same codon that changed the hydrophobic amino acid Ala to the negatively charged Asp and hydrophilic uncharged Ser respectively. The third member (case 8) had a similar substitution as in case 6; the hydrophobic amino acid Val was replaced by the negatively charged Glu.
Group C
As we expected, mutant p53 in case 9, which had a frameshift mutation at codon 195, did not bind the p53RE, whereas sample 12, which produced the wt p53, interacted strongly with the Fig. 2 ). These data and those of others (see Discussion) suggest that the biological and biochemical functions of p53 mutants are dependent on the specific missense mutations acquired in the p53 gene and probably the cellular environment in which they act.
Group B
As we expected mt p53 V173E, which failed to bind the p53RE in the bandshift assay, was also unable to transactivate it.
Group C As we mentioned, p53 mutant R273H, in case 10, was accompanied by the wt p53 allele. Thus, we could not exclude the possibility that DNA binding was achieved by heterotetramers containing the normal and mt p53 proteins (Stenger at al, 1992) .
Therefore, to clarify the picture we performed two kinds of experiments: first, we co-transfected the mt p53 plasmid alone with the reporter plasmid and then the mt with the wt p53 at ratios 1:1 and 4:1. The total amount of transfected mutant and wt p53 plasmid DNA was always 1 jg. As shown in Table 2 and Figure 2 mutant R273H was unable alone to activate the MDM2-p53RE. However, when mt and wt p53 plasmids were mixed at ratios 1:1 and 4:1 and co-transfected with the reporter plasmid the luciferase activity was increased from basal levels to 40% and 61% respectively. This result, as we will discuss later, suggests a dominant positive effect of inactive p53 mutant R273H over wt p53.
DISCUSSION
In the present work, we examined the ability of mutant p53 proteins derived from selected lung carcinomas to bind the MDM2-pS3RE. The findings were correlated with MDM2 mRNA and protein levels. Furthermore, we constructed four of these p53 mutants and studied their transactivation abilities by co-transfecting them with a reporter plasmid carrying the MDM2-pS3RE into the p53 null non-small-cell lung carcinoma cell line (NSCLC)
H1299.
Selection was based on certain criteria that allowed us the study of a homogeneous cancerous population as far as p53 and MDM2 expression is concerned. The cases were placed in three groups (see Materials and methods).
DNA-binding experiments revealed that three out of the five p53 mutants of group A (cases 1, 2 and 5) retained their DNAbinding properties. Their mutations were detected at codons 157 (V->F), 234 (Y->C) and 209 (R -*T). As all these cases showed overexpression of various MDM2 gene products due to increased transcription and not to MDM2 gene amplification, we suggested that certain p53 missense mutations, apart from stabilizing p53 Gottlieb and Oren, 1996) , generate proteins that may maintain several of the wt p53 properties and possibly acquire novel ones. The molecular basis of the effect that missense mutations have on the behaviour of p53 is not clear. One possible explanation relies on the charge difference they introduce into the p53 amino acid sequence. Interestingly, the substitutions in p53 mutants V157F and Y234C were conservative and thus did not alter the net charge of molecule. Similar were the findings of Zhang et al. (1993a) , Park et al. (1994) and Niewolik et al. (1995) . In their studies 'hotspot' p53 mutants, derived from different cell lines, were tested for their ability to bind the original consensus p53 DNA binding site (p53 CON) (Funk et al, 1992) . The mutants with DNA-binding activity had substitutions that retained the net charge of p53 and, furthermore, they maintained the ability to transactivate the p53 CON. In contrast, although the amino acid change in p53 mutant R209T was non conservative, it interacted with the MDM2-p53RE strongly. A probable interpretation could reside on the secondary structure that this substituation participates and the context in which this structure folds. Thus, position 209 lies in a 3-turn of the ,B-sandwich region of p53 and the relative frequency of occurrence for Thr in ,B-turn is higher than Arg (Creighton, 1984) . It is therefore possible that this particular substitution does not disrupt the secondary structure of the [-turn and the conformation of p53 protein generally. Crook et al. (1994) studying the growth and transformation suppression functions of a large series of mutants observed that two tumour-derived point mutants, p53 R175P and R181L, activated the MDM2-p53 RE as wt p53 did in primary rat embryo fibroblasts and Saos-2 cells. They detected, by Western blotting, elevated levels of several MDM2 protein isoforms. Both mutations were non-conservative and concerned the highly sensitive in alterations loop L2 and ahelix HI of the DNA binding domain of p53 (Cho et al, 1994) . Interestingly, both substitutions have a higher relative frequency of occurrence in the aforementioned secondary structures than Arg (Creighton, 1984) . Three additional reports by Chen et al (1993 ), Ory et al (1994 and Kawamura et al (1996) provide evidence that could support both sides. These groups studied the biological properties of several p53 mutants and observed a diversity in their functions making the picture of mutants p53 behaviour much more complex. Our opinion is that net charge difference is an important factor in predicting the binding behaviour of mt p53 as all the mutants in the present work that did not associate with the responsive element (mutants R158G and E258G from group A and all the mutants of group B) had substitutions that altered its net charge. However, steric effects, hydrophobicity and interaction with other proteins may also play a role.
The binding affinity of the mutants we examined was similar to that of the in vitro translated wt p53 used as control (Figure lB, lane 3). Niewolik et al. (1995) examining the affinity of p53 mutant proteins for the MDM2-p53RE, noticed a more than ten-fold reduction in their binding activity. These differences may reflect either a conformational and/or cell type specific effect. Several investigators have shown that wt and mt p53 may regulate certain promoters in a specific cell type manner (Grinsberg et al, 1991; Santhanam et al, 1991; Chin et al, 1992; Subler et al, 1992; Mack et al, 1993; Haupt et al, 1996; Rowan et al, 1996) ; for example the PCNA promoter was not repressed by wt p53 in the study of Mack et al (1993) using cervical epithelium cells but the same promoter was repressed by wt p53 in the study of Subler et al (1992) using Hela or Vera cells. Rowan et al. (1996) demonstrated that mutant p53 R175P could induce growth arrest but not apoptosis in Saos-2 and H1299 cells, whereas HeLa and H358 cells retained some apoptotic function after R175P expression. This cell-type effect may be due to specific cellular co-factors that couple with the activated form of p53, thus modulating its function.
The p53 mutant proteins in specimens 3 and 4, which also showed MDM2 overexpression, did not bind the MDM2-pS3RE. It seems that in these cases MDM2 overexpression is due either to a p53-independent mechanism or to an indirect mode of action of mt p53. The basis for both mechanisms possibly relies on the way MDM2 gene is organized. The MDM2 gene possesses two promoters P1 and P2 (Figure 3 ). P1 is a p53-independent promoter located upstream from exon 1 and is active at basal constitutive levels and P2 is the p53-dependent promoter located in intron 1 and contains the p53 RE accompanied by the general transcription element TATA box (Zauberman et al, 1995a) . In the first case, the p53-independent mechanism of MDM2 overexpression is possibly activated by alterations in the regulatory elements of P1. Although our experiments did not reveal MDM2 gene amplification, we cannot exclude the possibility of regional gene alterations (e.g. deletion of silencer elements), which could participate in this putative mechanism. In the second, mutant p53 may favour transcription in a general way. This assumption is based on several observations. It has already been shown that the N-terminus of wt p53 directly interacts with TBP (TATA-binding protein) and other general transcription factors (Martin et al, 1993; reviewed by: Zambetti and Levine, 1993; Gottlieb and Oren, 1996; Ko and Prives, 1996; Oren and Prives, 1996; Levine, 1997) . The presence of p53 binding sites near the TATA element possibly allows the nucleation on these promoters, thus enhancing transcriptional activity. In the case of mtp53 defective in DNA binding, the interaction with these transcription factors may be preserved and a general activation of P2 may be achieved. In accordance with this speculation is the finding of Martin et al (1993) , who observed that mt p53 V218G, which was bound with TBP, did activate a promoter with p53 binding sites in vivo, although the DNA binding activity of the mutant was abolished.
The findings in group A were further enforced by the observations in group B. The mutants in this group (A138D, A138S and V173E) did not bind the MDM2-pS3RE and were not accompanied by MDM2 expression. Codon 138 is localized near the transcriptional activation domain of p53. The integrity of the transactivation domain is shown to be critical for 'gain of function' p53 mutants (Lin et al, 1995) . Possibly these mutants, apart from losing their DNA binding properties, suffer a conformational change in the N-terminus domain that interferes with their ability to interact with factors of the transcription machinery. Codon 173 is involved in stabilizing interactions between loops L2 and L3 of p53 protein. Mutations at this region are considered among the most disruptive for p53 functions (Prives, 1994) . The four samples included in the heterogeneous group C provided additional evidence concerning the functions of mt and wt p53. In sample 9, p53 did not show binding activity because the frameshift mutation at codon 195 altered its reading frame producing either a non-functional mRNA or an altered protein with unknown functions. MDM2 overexpression in sample 12 is possibly caused by constant stimulation of the MDM2 gene by the accumulated wt p53. Normally wt p53 has a short half-life Gottlieb and Oren, 1996) , but cellular stress (Hall et al, 1996) and certain proteins, including MDM2, can induce stabilization of the protein (Momand et al, 1992) . Recently, Haupt et al (1996) demonstrated that MDM2 overexpression in H1299 cells resulted in effective protection from apoptosis. Loss of p53 induced apoptosis even without a concomitant loss of GI arrest could contribute to cancer progression. This mechanism of action could exist in our case as well. Finally, p53 mutants R273H and C275Y behaved in a similar manner as mutants in samples 1, 2 and 5. As these cases retained the wt p53 allele we hypothesized that MDM2 protein isoform overexpression was achieved either by the mutant in a wt p53-independent manner (wt p53 allele nonfunctional) or by a dominant positive effect of the mt p53 on the functional wt p53.
To examine the credibility of the hypotheses we have suggested above, we constructed four of these p53 mutants, two from group A, V157F and R209T, and one from group B, V173E, and C, R273H, co-transfected them with a luciferase reporter plasmid carrying the MDM2-pS3RE, in the p53 null H1299 cell line and studied their transactivation abilities. Mutant V157F enhanced luciferase expression at about 72% ( Figure 2, Table 2 ) of the wt p53 vector conforming our initial speculation that, MDM2 overexpression in certain lung carcinomas may be due to a 'gain of function' mutant p53 phenotype (Gorgoulis et al, 1996a,b) . In contrast, mutant R209T, which showed a strong interaction with the responsive element, failed to stimulate it. This finding may be due to determinants of the H1299 cellular context that altered the function of the protein. The effect of the cellular environment on wt and mt p53 activities, as we mentioned, is gradually becoming clearer (Oren and Prives, 1996) . In the present case, R209T was detected in a small-cell lung carcinoma (SCLC), whereas H1299 is Functions of mutant p53 and MDM2 proteins in lung cancer 383 a non-small-cell lung carcinoma (NSCLC)-derived cell line. Although from a histogenetic point of view all histological variants of bronchogenic carcinoma have a common origin, SCLCs are much more aggressive and are treated differently than NSCLCs (Mackay et al, 1991) . Whereas transfection with V173E, as we expected, showed no surprises ( Figure 2 , Table 2 ) transfection with R273H showed some interesting results. More specifically, when R273H was introduced in the cells alone with the reporter plasmid no luciferase activity was observed but when R273H and wt p53 expression vectors were mixed in a 1:1 and 4:1 ratio, luciferase activity was increased gradually from basal levels to 40% and 61% respectively (Figure 2, Table 2 ). This finding conformed the hypothesis we stated and suggested that dominant negative inhibition by mt p53 is not the rule and that certain p53 mutants, depending on the binding element and possibly the appropriate environment, have a 'positive effect' on wt p53 function. Similar were the results of Zhang et al (1993b) using the p53CON element. In their study, they proposed that the relative ratio of mt to wt p53 in the heterotetramers they form is important for transactivation.
Taking together the above data, we propose the following hypothesis ( Figure 3 ): in a normal cell under stress, MDM2 can be transactivated only when wt p53 has activated the targets that mediate its action (e.g. gadd45, waf-Jlcip-1). When the cell contains relatively large amounts of wt p53, it binds transiently the p53RE of MDM2, triggering MDM2 expression that eventually terminates p53 cycle arrest mediated signal. In contrast, constantly elevated levels of mt or wt p53 in lung carcinoma cells permanently stimulate the MDM2 gene (directly or indirectly), producing high levels of MDM2 mRNA. Excess MDM2 mRNA is probably responsible, via complex mechanisms (Barak et al, 1994; Zauberman et al, 1995a) , for the production of various MDM2 proteins, several of which do not participate in the autoregulatory loop with p53 (Gorgoulis et al, 1996b) . These proteins possibly add novel oncogenic properties to the cell (Sigalas et al, 1996) .
In conclusion, the present study suggests that deregulation of the p53/MDM2 autoregulatory feedback loop, in a subset of lung carcinomas, may be due to either a 'gain of function' mt p53 phenotype or to a dominant positive effect of certain p53 mutants on the wt p53 protein.
